Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?

Executive Summary

Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal

You may also be interested in...



Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy

Pfizer's Zoloft may feel the greatest negative performance impact from FDA's decision to require a class-wide black box warning for antidepressants

Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy

Pfizer's Zoloft may feel the greatest negative performance impact from FDA's decision to require a class-wide black box warning for antidepressants

Merck Sees Slightly More Success With External Rx Than Internal Candidates

Merck has a slightly higher success rate with drug candidates developed through external licensing deals than with internally discovered compounds, Merck Senior Director-Strategic Research Initiatives, External Scientific Affairs Ronald Newbold said

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel